Video

The Aftermath of Hepatitis C Drugs on Specialty Spending

Author(s):

Davy James, Managing Editor

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.

Related Videos
Pharmacist helping a patient with medication -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
Patient receiving cancer treatment infusion -- Image credit: UlrikaArt | stock.adobe.com
Related Content
Pharmacist, customer or support in shop with medicine, shopping with professional help. Pharmacy, people or together for healthcare service with advice for dosage, pill information for woman with flu
March 31st 2025

Expert Q&A: Role of Pharmacists in COVID-19 Care, Prevention Continues to Evolve

Luke Halpern, Assistant Editor Corey Frederick, PharmD, BCPS, BCIDP, CPh
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Herpes Zoster as an Early Indicator of HIV: Clinical Insights
March 31st 2025

Herpes Zoster as an Early Indicator of HIV: Clinical Insights

Emilia Welch, PharmD, MBA
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Gene therapy innovation for hemophilia treatment - scientific visualization for medical research
March 28th 2025

FDA Approves Fitusiran For Prophylactic Hemophilia A, B Treatment Regardless of Inhibitor Status

Luke Halpern, Assistant Editor
Kidney dialysis displayed on tablet -- Image credit: frank | stock.adobe.com
March 28th 2025

Peritoneal Dialysis May Be Feasible, Safe Long-Term Treatment for Patients With CKD

Gillian McGovern, Associate Editor